Bozhinovski, Georgi

Preferred name
Bozhinovski, Georgi
Official Name
Bozhinovski, Georgi
Main Affiliation
Email
gjorgji.bozhinovski@medf.ukim.edu.mk

Settings

Now showing 1 - 6 of 6
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Satisfaction Level of Rheumatoid Arthritis Patients Enrolled in the Treatment with Subcutaneous Tocilizumab. Journal of Autoimmune Diseases and Rheumatology
    (Karachi: Synergy Publishers, 2020)
    Filip Guchev
    ;
    ;
    D. Antova
    ;
    B. Osmani
    ;
    M. Nikolovska Kotevska
    Background: The introduction of biological-Disease Modifying Agents (bDMARDs) has allowed serious improvement in the treatment of patients with rheumatoid arthritis (RA) by providing a better quality of life (QoL). Such improvements have been shown in patients using subcutaneous form of Tocilizumab SC (TCZ-SC), a humanized monoclonal antibody against IL-6 receptor. Objective: To assess the subcutaneous treatment satisfaction level and to evaluate the epidemiological profile of RA patients treated with TCZ-SC in North Macedonian Patients with RA. Methods: An observational study was conducted at the University Rheumatology Clinic in Skopje between October 1st and December 15th 2018, including 48 patients who have received TCZ-SC. In order to obtain patient’s satisfaction level and to evaluate the epidemiological characteristics of the patients, a standardized questionnaire was developed. Results: The mean age of the patient’s cohort was 50.9 years and 88.5% of the patients were females. More than half of the patients (58%) had high disease activity with mean disease duration of 5.35 years. Eighty three percent of the patients were entitled to receive subcutaneous TCZ because of the insufficient efficacy of previous treatment, All patients enrolled in the treatment with TCZ-SC, reported to be satisfied or very satisfied with the subcutaneous application of TCZ. They were also very satisfied with the previous education and the opportunity to receive the treatment at home. Conclusions: Tocilizumab as an efficient and well tolerated bDMARD is becoming a standard of care in the treatment of patients suffering from RA, offering unprecedented benefits for QoL improvement and satisfying the patients’ needs for modern and effective treatment.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Overlap syndrome in refractory case
    (Macedonian Association of Anatomists, 2022)
    Filip Gucхev
    ;
    ;
    ;
    This is a report of the case of a 23 years-old girl with refractory dermatomyositis, complications in her treatment and the unfortunate fatal end. Dermatomyositis can be a notoriously difficult disease to treat, and remission is often elusive or short-lived despite aggressive therapy. In the years after the diagnosis, many aggressive modalities of treatment were tried, including rituximab. The patient had frequent exacerbations of the myositis, needed aggressive therapy and developed many side effects associated with the treatment. Most common of these were infections. After suffering severe stress, she developed fever, was diagnosed with sepsis and despite exhaustive treatment at the intensive care unit she passed away.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    SECONDARY SJOGREN’S SYNDROME IN PATIENTS WITH RHEUMATOID ARTHRITIS
    (Институт за јавно здравје на Република Северна Македонија, 2022)
    Filip Guchev
    ;
    ;
    ;
    Snezhana Perchinkova-Mishevska
    ;
    Natali Jordanovska-Gucheva
    Secondary Sjogren’s syndrome (sSS) is a connective tissue disease characterized by xeropthalmia and xerostomia, associated with another autoimmune disease. The prevalence of sSS in patients with rheumatoid arthritis (RA) is different in different countries, but is assumed at 10% of all RA patients and 20% of these have sub-clinical manifestations. This is a large subpopulation of patients with RA, especially taking into account that the clinical implications of their coexistence are not well explored. Aims: To analyze the effects of sSS on RA, the association between this syndrome and disease activity and disease evolution, presence of serological and immunological markers, disease duration and quality of life in patients with RA. Material and methods: We examined 42 patients, at the age of 18 to 70 years, diagnosed according to the criteria for classification and diagnosis by EULAR (2010). Twenty patients were diagnosed with RA and sSS, and 22 patients with RA without sSS. The groups were comparable regarding age, sex and disease duration. We analyzed the incidence of sSS, association with age, sex, demographic data, disease duration, extraarticular manifestations, and serologic tests (positive RF, anti-CCP) were also made. Disease activity was assessed by disease activity score (DAS28) and quality of life by the health assessment questionnairedisability index (HAQ-DI). The number of tender and swollen joints was assessed, as well as pain level by using the visual analogue scale (VAS), sedimentation rate (ESR), CRP, and immunological tests (SSA, SSB, antidsDNA, ANA, antiU1snRNP) were also made. Results: In the analyzed patients there was no statistically significant difference in ESR, CRP, DAS28, HAQ-DI, seropositivity of RF and anti-CCP and the presence of antidsDNA, ANA or antiU1snRNP and disease duration. Patients in the RA group had more tender, swollen joints and VAS. There was a statistically significant difference in SSA and SSB levels. There was no significant difference in the treatment of patients from both groups. Conclusion: There was no statistically significant difference in the level of disease activity and quality of life in patients with RA compared to sSS group.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Satisfaction Level of Rheumatoid Arthritis Patients Enrolled in the Treatment with Subcutaneous Tocilizumab
    (Synergy Publishers, 2020)
    Filip Gucev
    ;
    Lj Damjanovska-Krstikj
    ;
    Dubravka Antova
    ;
    Bashim Osmani
    ;
    Mimoza Nikolovska Kotevska
    Abstract: Background: The introduction of biological-Disease Modifying Agents (bDMARDs) has allowed serious improvement in the treatment of patients with rheumatoid arthritis (RA) by providing a better quality of life (QoL). Such improvements have been shown in patients using subcutaneous form of Tocilizumab SC (TCZ-SC), a humanized monoclonal antibody against IL-6 receptor. Objective: To assess the subcutaneous treatment satisfaction level and to evaluate the epidemiological profile of RA patients treated with TCZ-SC in North Macedonian Patients with RA. Methods: An observational study was conducted at the University Rheumatology Clinic in Skopje between October 1st and December 15th 2018, including 48 patients who have received TCZ-SC. In order to obtain patient’s satisfaction level and to evaluate the epidemiological characteristics of the patients, a standardized questionnaire was developed. Results: The mean age of the patient’s cohort was 50.9 years and 88.5% of the patients were females. More than half of the patients (58%) had high disease activity with mean disease duration of 5.35 years. Eighty three percent of the patients were entitled to receive subcutaneous TCZ because of the insufficient efficacy of previous treatment, All patients enrolled in the treatment with TCZ-SC, reported to be satisfied or very satisfied with the subcutaneous application of TCZ. They were also very satisfied with the previous education and the opportunity to receive the treatment at home. Conclusions: Tocilizumab as an efficient and well tolerated bDMARD is becoming a standard of care in the treatment of patients suffering from RA, offering unprecedented benefits for QoL improvement and satisfying the patients’ needs for modern and effective treatment.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    The diagnostic value of anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis
    (2007-06-13)
    L. Damjanovska Rajcevska
    ;
    V. Jovanovska
    ;
    ;
    N. Marina
    ;
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,